Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: Clinical and economic consequences

PharmacoEconomics

Volumn 32, Issue 1, 2014, Pages 5-13

  Barletta, Jeffrey F ^a   Sclar, David A ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

CASE CONTROL STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GOLD STANDARD; HEALTHCARE ASSOCIATED INFECTION; HIGH RISK PATIENT; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL DISCHARGE; HUMAN; ICD-9; LENGTH OF STAY; META ANALYSIS; MORBIDITY; MORTALITY; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STOMACH PH; STRESS ULCER; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

COST-BENEFIT ANALYSIS; DRUG UTILIZATION; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PROTON PUMP INHIBITORS; STRESS, PSYCHOLOGICAL;

EID: 84898833615     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0119-5     Document Type: Review

References (62)

1. Barletta JF, Lat I, Micek S, Cohen H, Olsen K, Haas C. Off label use of gastrointestinal medications in the intensive care unit. J Intensive Care Med. 2011 (in press).
2. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004;32(10):2008-13. (Pubitemid 39372533)
3. Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Critical care (London, England). 1999;3(6):145-9. (Pubitemid 30004542)
4. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330(6):377-81. (Pubitemid 24045653)
5. Herzig SJ, Vaughn BP, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med. 2011;171(11):991-7.
6. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. Critical care (London, England). 75. 2001;5(6):368-75.
7. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693-705.
8. Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of protonpump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38(4):1197-205.
9. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am. J Health Syst Pharm. 1999;56(4):347-79.
10. Krag M, Perner A, Wetterslev J, Moller MH. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiologica Scandinavica. 2013;57(7):835-47.
11. Cook D, Heyland D, Griffith L, Cook R, Marshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med. 1999;27(12):2812-7. (Pubitemid 30027202)
12. Hurt RT, Frazier TH, McClave SA, Crittenden NE, Kulisek C, Saad M, et al. Stress prophylaxis in intensive care unit patients and the role of enteral nutrition. JPEN J Parent Enter Nutr. 2012;36(6):721-31.
13. Marik PE. Stress ulcer prophylaxis in the new millennium! ICU Dir. 2010;1(1):12-6.
14. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38(11):2222-8.
15. van der Voort PH, Zandstra DF. Pathogenesis, risk factors, and incidence of upper gastrointestinal bleeding after cardiac surgery: is specific prophylaxis in routine bypass procedures needed? J Cardiothorac Vasc Anesth. 2000;14(3):293-9. (Pubitemid 30415929)
16. Rosen HR, Vlahakes GJ, Rattner DW. Fulminant peptic ulcer disease in cardiac surgical patients: pathogenesis, prevention, and management. Crit Care Med. 1992;20(3):354-9.
17. Herzig SJ, Rothberg MB, Feinbloom DB, Howell MD, Ho KK, Ngo LH, et al. Risk factors for nosocomial gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill patients. J Gen Intern Med. 2013;28(5):683-90.
18. Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin N Am. 2009;38(2):245-65.
19. Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med. 2005;33(4):760-5.
20. Solouki M, Marashian S, Kouchak M. Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos. 2009;8:37-42.
21. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997;42(6):1255-9. (Pubitemid 27343453)
22. Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepato Gastroenterol. 2004;51(57):757-61. (Pubitemid 38590958)
23. Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507-20 (quiz 21).
24. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791-7. (Pubitemid 28135985)
25. Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275(4):308-14.
26. Guillamondegui OD, Gunter Jr OL, Bonadies JA, Coates JE, Kurek SJ, DeMoya MA, et al. Practice management guidelines for stress ulcer prophylaxis. EAST Practice Management Guidelines Committee. http://wwweastorg/resources/treatment- guidelines/stress-ulcer-prophylaxis (2008). Accessed 3 July 2013.
27. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
28. Barletta JF, Erstad BL, Fortune JB. Stress ulcer prophylaxis in traumapatients.Critical care (London, England). 2002;6(6):526-30.
29. Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207-11.
30. Issa IA, Soubra O, Nakkash H, Soubra L. Variables associated with stress ulcer prophylaxis misuse: a retrospective analysis. Dig Dis Sci. 2012;57(10):2633-41.
31. Judd WR, Davis GA, Winstead PS, Steinke DT, Clifford TM, Macaulay TE. Evaluation of continuation of stress ulcer prophylaxis at hospital discharge. Hosp Pharm. 2009;44:888-93.
32. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):3118-22.
33. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Therap. 2003;17(12):1503-6. (Pubitemid 36833294)
34. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Therap. 2005;21(10):1203-9. (Pubitemid 40733485)
35. Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25(2):214-20.
36. Murphy CE, Stevens AM, Ferrentino N, Crookes BA, Hebert JC, Freiburg CB, et al. Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy. 2008;28(8):968-76.
37. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother. 2007;41(10):1611-6. (Pubitemid 47479789)
38. Zeigler AJ, McAllen KJ, Slot MG, Barletta JF. Medication reconciliation effect on prolonged inpatient stress ulcer prophylaxis. Ann Pharmacother. 2008;42(7):940-6.
39. Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA Jr. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106(4):270-3.
40. Hussain S, Stefan M, Visintainer P, Rothberg M. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J. 2010;103(11):1103-10.
41. Koczka CP, Geraldino-Pardilla LB, Goodman AJ. Physicians' opinions of stress ulcer prophylaxis: survey results from a large urban medical center. Dig Dis Sci. 2013;58(3):777-81.
42. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120-8.
43. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784-90.
44. Meijvis SC, Cornips MC, Voorn GP, Souverein PC, Endeman H, Biesma DH, et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Resp J. 2011;38(5):1165-72.
45. Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085-90.
46. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989-95. (Pubitemid 41817660)
47. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950-5. (Pubitemid 46762758)
48. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955-60. (Pubitemid 39411203)
49. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693-703.
50. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391-8.
51. Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, et al. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ (Clinical research ed). 2013;347:f5416.
52. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-53. (Pubitemid 46021498)
53. Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Butto V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518-23.
54. Parker DR, Luo X, Jalbert JJ, Assaf AR. Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Med Econ. 2011;14(3):279-87.
55. Heyland D, Gafni A, Griffith L, Cook D, Marshall J, Fuller H, et al. The clinical and economic consequences of clinically important gastro-intestinal bleeding in critically ill patients. Clin Intensive Care. 1996;7:121-5. (Pubitemid 26290208)
56. Barkun AN, Adam V, Martel M, Bardou M. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health. 2013;16(1):14-22.
57. Thomas CP, Ryan M, Chapman JD, Stason WB, Tompkins CP, Suaya JA, et al. Incidence and cost of pneumonia in Medicare beneficiaries. Chest. 2012;142(4):973-81.
58. Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med. 2010;170(4):347-53.
59. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55(6):807-15.
60. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28(11):1219-27. (Pubitemid 47596558)
61. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200-5. (Pubitemid 44477543)
62. Udeh BL, Udeh C, Hata JS. Cost-effectiveness of stress ulcer prophylaxis: role of proton pump inhibitors. Am J Pharm Benefits. 2010;2(5):304-12.